Q4 2024 RESULTS Nasdaq Global Market: CCLD, CCLDP, CCLDO March 13, 2025 A leading provider of technology-enabled services and solutions that redefine the healthcare revenue cycle © CareCloud, Inc. 2025 Safe Harbor Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by term ...

Financial Data and Key Metrics Changes - For fiscal year 2024, the company reported revenue of $92.1 million and adjusted EBITDA of $11.7 million, exceeding guidance and street expectations [7] - Fourth quarter revenue was $32.3 million, a 14% increase from $28.4 million in the same period of 2023, driven by increased DAAP-related revenue streams [19] - Gross margin improved from 62.9% in Q4 2023 to 68.2% in Q4 2024, attributed to a favorable solution and channel partner mix [19] - Net loss for Q4 2024 was $0.1 million, significantly improved from a net loss of $4.1 million in Q4 2023 [21] - Non-GAAP net income for Q4 2024 was $5.5 million, or $0.30 per diluted share, compared to $4.6 million, or $0.26 per diluted share in the prior year [21] - Adjusted EBITDA for Q4 2024 was $8.8 million, up from $5.8 million in Q4 2023 [21] Business Line Data and Key Metrics Changes - The average revenue for the top 20 pharmaceutical manufacturers was $2.9 million, a 22% increase year-over-year [23] - The top five customers averaged over $9 million in revenue in 2024, with plans to elevate at least one more customer to this level in 2025 [12] Market Data and Key Metrics Changes - The net revenue retention rate improved to 121%, up from 105% in the previous year [23] - Revenue per FTE increased to $701,000, compared to $586,000 in the prior year [23] Company Strategy and Development Direction - The company aims to focus on operational excellence and customer centricity while transitioning to a subscription-based revenue model [5][6] - Plans to become a "Rule of 40" company over the next several years, emphasizing substantial operating leverage and predictable revenue streams [15][16] - The company is positioned in a $10 billion total addressable market with significant growth opportunities driven by increased pharma advertising spend on digital channels [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory and the strong demand for audience creation and dynamic audiences [48] - The company is committed to under-promising and over-delivering, maintaining a conservative approach while being encouraged by current visibility in the business [71] - The management highlighted the importance of monitoring FDA approvals and their impact on the pharmaceutical market [78] Other Important Information - The company completed the Medicx Health acquisition in Q4 2023, which is expected to enhance its service offerings and operational efficiency [20] - The transition from managed services to self-service for Medicx is largely complete, with growth in audience components being a key focus [100] Q&A Session Summary Question: Focus on customer centricity and strategy changes - Management emphasized increasing customer centricity and making it easier for clients to renew and expand their footprint [30] Question: Impact of subscription-based revenue model - The transition to a subscription model is expected to create more predictable and stickier revenue, particularly from the data component of DAAP deals [36] Question: Gross margin expansion drivers - Gross margin expansion was driven by product mix, particularly from DAAP, and while current margins are high, they may not be sustainable at that level [45][46] Question: Visibility into new DAAP deals and backlog - The company is seeing strong demand for DAAP solutions, with visibility into 2025 being significantly stronger than the previous year [52] Question: Timeframe for becoming a Rule of 40 company - Management indicated that achieving the Rule of 40 is a multi-year journey, likely taking 3 to 5 years [58] Question: Baseline growth expectations for next year - Management is optimistic about growth but will maintain a conservative approach in forecasting [70] Question: Customer acquisition costs for data vs transactional components - There is no material difference in customer acquisition costs between data and transactional components [90] Question: Transition of Medicx business from managed to self-service - The transition is largely complete, with growth in high-margin audience components being a focus [99]

Core Insights - Biotricity has expanded its intellectual property portfolio with 14 new patents, bringing the total to 15 issued patents and 14 pending, highlighting its commitment to enhancing patient care through advanced diagnostic solutions [1][4] - The new patents focus on a multi-sensor patch device platform that can function as both a patch and a watch, allowing for versatile integration in remote patient monitoring [2][3] - The innovations aim to streamline diagnostic processes, enabling simultaneous diagnostic studies, which can significantly reduce delays in diagnosis and expedite treatment for patients [3][4] Company Overview - Biotricity is a Technology-as-a-Service (TaaS) company that specializes in diagnostic and chronic disease management solutions for healthcare providers and consumers [1][5] - The company aims to reform the healthcare market by bridging gaps in remote monitoring and chronic care management, providing comprehensive solutions for both medical and consumer markets [5]

Core Insights - The integration between Reclaim Health and WEX aims to transform the health and benefits landscape for employers and employees through AI-powered claims data and analytics [1][2] - This collaboration is designed to empower employees in managing healthcare costs and optimizing health coverage, while also helping employers control rising healthcare expenses [2][3] Company Overview - Reclaim Health is an AI-powered, claims-driven healthcare financial advocacy platform that assists families in managing healthcare expenses and optimizing health coverage [4] - The platform focuses on proactive management of healthcare spending, optimization of benefit offerings, and maximizing employee benefits [4] Integration Details - The integration combines Reclaim's innovative platform with WEX's benefits administration technology, creating a fully integrated solution that provides real dollar savings for employees and helps employers manage costs [2][3] - The partnership is expected to deliver enhanced claims analysis, proactive cost-saving recommendations, streamlined benefits selection, and personalized support for employees throughout the year [5]

Core Insights - Nextech is showcasing enhancements to its revenue cycle management (RCM) platform at the AAD Annual Meeting, emphasizing its role in reducing denied claims and increasing reimbursement for specialty providers [1][4]. Group 1: Company Overview - Nextech is a leader in healthcare technology and practice management solutions, focusing on specialty providers since 1997 [5]. - The company serves over 16,000 physicians and more than 60,000 office staff across various clinical specialties, including dermatology, med spa, ophthalmology, orthopedics, and plastic surgery [5]. Group 2: RCM Solutions - Nextech's RCM services are designed to address the complexities of managing a practice's revenue cycle, particularly in light of rising claim denials and evolving payer requirements [2]. - The RCM platform is fully integrated within Nextech's specialty-specific system and offers customizable services tailored to individual practice needs, such as collections for unpaid patient responsibilities and patient payment plans [3]. Group 3: Industry Challenges - The increase in insurance claim denials has led to significant challenges for providers, impacting cash flow and creating operational inefficiencies [2]. - Nextech RCM aims to alleviate these challenges by streamlining billing workflows and reducing administrative burdens, allowing providers to focus on patient care [2].

Core Insights - Aclarion, Inc. is expanding the access of its Nociscan technology across multiple sites in New York and New Jersey to address the growing demand for chronic low back pain solutions [1][2] - The expansion is supported by enhanced remote operations capabilities and increased availability of Magnetic Resonance Spectroscopy (MRS) within RadNet [1][2] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][5] Strategic Partnerships - Lenox Hill Radiology operates 79 locations in New York and has adopted Nociscan to enhance access for leading spine physicians [2][3] - New Jersey Imaging Network, with 33 locations, was the first in NJ to adopt Nociscan, facilitating support for local and out-of-market referrals [3]

Core Insights - Aclarion, Inc. has established a commercial agreement with Scripps Health to expand access to its Nociscan technology for chronic low back pain diagnosis in the San Diego area [1][2][3] - Nociscan utilizes MR Spectroscopy and AI to help physicians identify the sources of chronic low back pain, distinguishing between painful and nonpainful discs [3][5] - The agreement will benefit over 3.2 million people in the greater San Diego Metro area, enhancing the capabilities of leading spine physicians at Scripps Health [1][2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging biomarkers and proprietary AI algorithms [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in diagnosing disc-related pain [3][5] - The technology processes MRS data from MRI machines to quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [5][6] Industry Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide [3] - The partnership with Scripps Health is expected to enhance diagnostic capabilities and treatment strategies for patients suffering from chronic low back pain [2][3]

Core Points - Aclarion, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025, to March 5, 2025, to solicit additional votes on proposals outlined in the definitive proxy statement filed with the SEC on February 3, 2025 [2][5][6] - The reconvened Special Meeting will take place at the company's corporate office in Broomfield, Colorado, and stockholders as of the record date of January 6, 2025, are encouraged to vote promptly [3][4] - Proxies submitted for the Special Meeting will remain valid unless revoked, and stockholders can change their votes until March 4, 2025, at 11:59 p.m. Mountain Time [4] Company Overview - Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS) and a proprietary biomarker to enhance clinical treatments for low back and neck pain, addressing a market valued at $134.5 billion in the U.S. [7] - The company is integrating Artificial Intelligence (AI) into its quality control processes to identify poor MRS study data and is exploring AI and machine learning applications to analyze spectroscopy data for better clinical outcome associations [7]

Financial Overview - Full year revenues increased by 4.5%, net income rose by 31.5%, operating income grew by 32.9%, and adjusted EBITDA was up by 9% [7][39] - For Q4 2024, revenues were $74.2 million, up 5.2% from $70.6 million in Q4 2023, with subscription products accounting for 96% of total revenues [25][26] - Adjusted EBITDA for Q4 was $16.2 million, reflecting a 1.3% increase, with an adjusted EBITDA margin of 21.8% [30][39] Business Line Performance - Subscription revenue growth was driven by CredentialStream (28% growth), ShiftWizard (17% growth), and the Competency Suite (8% growth), while legacy products saw declines totaling approximately $1 million [27] - Professional Services revenues increased by 15.7% to $3.1 million [26] Market Data - Remaining performance obligations were $621 million, up from $541 million year-over-year, with expectations of approximately 40% conversion over the next 12 months [27] - The company maintains a strong cash balance of $97.2 million with no long-term debt, positioning it well for potential M&A opportunities [8][22] Company Strategy and Industry Competition - The company declared 2025 as the "Year of the Platform," focusing on enhancing interoperability among its applications and expanding its platform capabilities [11][13] - The HStream platform is expected to drive innovation and efficiency, allowing for faster development of new applications [13][14] Management Commentary on Operating Environment and Future Outlook - Management anticipates organic revenue growth between $302 million and $307 million for 2025, with net income expected between $19.2 million and $21.4 million [8][39] - The company is optimistic about its strong sales pipeline and expects to see growth concentrated in the second half of 2025 [79] Other Important Information - The board approved a dividend increase of 10.7% to $3.1 per share, reflecting confidence in the company's growth strategies [43] - The company has been recognized for its software applications, with the HealthStream Learning Center named the top software in healthcare by G2 [16][18] Q&A Session Summary Question: What will it take to achieve a 7% to 10% growth profile? - Management indicated that achieving this growth would require a combination of organic growth (5% to 7%) and inorganic growth (1% to 3%) through M&A [66][67] Question: Can you quantify the headwinds faced while shifting customers from Perpetual to SaaS? - Management suggested that the headwinds could be similar to the previous year, around 1% to 2% [74] Question: Are you seeing efficiencies from AI in product development? - Management confirmed that they are exploring AI applications internally to improve efficiency, though initial costs may rise before benefits are realized [84][86] Question: How successful have you been in incorporating pricing escalators into new contracts? - Management reported a success rate of over 95% in incorporating escalators into new contracts, which is expected to provide a new base level of growth [92][94] Question: When will the HealthStream Learning Experience (HLX) be fully launched? - The HLX is currently available for sale, with expectations for increased sales in the second half of the year following successful pilot programs [101]

As filed with the Securities and Exchange Commission on December 17, 2024. Registration No. 333-280945 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Wellgistics Health, Inc. (Exact name of registrant as specified in its charter.) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Number) Delaware 8090 93-3264234 (IRS Employer Identification No. ...